Cheviot Value Management LLC lowered its holdings in CVS Health (NYSE:CVS) by 4.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,306 shares of the pharmacy operator’s stock after selling 1,652 shares during the period. CVS Health comprises 1.3% of Cheviot Value Management LLC’s holdings, making the stock its 23rd largest position. Cheviot Value Management LLC’s holdings in CVS Health were worth $2,560,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of CVS. Wealthcare Advisory Partners LLC lifted its position in shares of CVS Health by 330.3% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 991 shares during the last quarter. Fieldpoint Private Securities LLC lifted its position in shares of CVS Health by 333.3% during the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 1,000 shares during the last quarter. Cerebellum GP LLC purchased a new position in shares of CVS Health during the 4th quarter valued at $130,000. Capital Analysts LLC lifted its position in shares of CVS Health by 240.1% during the 4th quarter. Capital Analysts LLC now owns 3,177 shares of the pharmacy operator’s stock valued at $137,000 after buying an additional 2,243 shares during the last quarter. Finally, Valeo Financial Advisors LLC purchased a new position in shares of CVS Health during the 3rd quarter valued at $159,000. 84.01% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have recently commented on CVS. Leerink Swann set a $85.00 price target on CVS Health and gave the company a “buy” rating in a research report on Tuesday, April 10th. ValuEngine cut CVS Health from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Vetr cut CVS Health from a “buy” rating to a “hold” rating and set a $77.11 price target on the stock. in a research report on Thursday, January 4th. Morgan Stanley raised CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 price target on the stock in a research report on Friday, January 5th. Finally, SunTrust Banks upped their price target on CVS Health to $90.00 and gave the company a “buy” rating in a research report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. CVS Health has a consensus rating of “Buy” and a consensus price target of $86.65.
Shares of CVS opened at $66.60 on Wednesday. The stock has a market cap of $66,066.33, a P/E ratio of 11.29, a P/E/G ratio of 1.11 and a beta of 1.05. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.52 and a current ratio of 1.02. CVS Health has a 52-week low of $60.14 and a 52-week high of $84.00.
CVS Health (NYSE:CVS) last announced its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.04. The business had revenue of $48.39 billion for the quarter, compared to analyst estimates of $47.54 billion. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.71 EPS. research analysts expect that CVS Health will post 6.32 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 3rd. Shareholders of record on Monday, April 23rd will be paid a $0.50 dividend. The ex-dividend date is Friday, April 20th. This represents a $2.00 dividend on an annualized basis and a yield of 3.00%. CVS Health’s dividend payout ratio is currently 33.90%.
In other CVS Health news, EVP Helena Foulkes sold 19,965 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $71.04, for a total value of $1,418,313.60. Following the transaction, the executive vice president now directly owns 65,072 shares in the company, valued at approximately $4,622,714.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.61% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “CVS Health (CVS) Shares Sold by Cheviot Value Management LLC” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/04/25/cvs-health-cvs-shares-sold-by-cheviot-value-management-llc.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.